June 2, 2021
An international group of twelve experts recently published a consensus report examining the state of the evidence and offering recommendations to guide the screening, diagnosis, and treatment of individuals with ADHD-SUD comorbidity.[1]
In a clear sign that we are still in the early stages of understanding this relationship, five of the thirteen recommendations received the lowest recommendation grade (D), eight received the next-lowest (C), and none received the highest (A and B). The lower grades reflected the absence of the highest level of evidence, obtained from meta-analyses or systematic reviews of relevant randomized controlled trials (RCTs).
Nevertheless, with these limitations in mind, the experts agreed on the following points:
Diagnosis
Treatmen
The grade C recommendations included considering adequate medical treatment of both ADHD and SUD; integrating ADHD treatment with SUD treatment as soon as possible;
Cleo L. Crunelle at al., "InternationalConsensus Statement on Screening, Diagnosis and Treatment of Substance UseDisorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder," European Addiction Research, publishedonline March 6, 2018, DOI: 10.1159/000487767.